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Abstract
Background: There is strong evidence that culture-based methods detect only a small proportion of bacteria present in the
respiratory tracts of cystic fibrosis (CF) patients.
Methodology/Principal Findings: Standard microbiological culture and phenotypic identification of bacteria in sputa from
CF patients have been compared to molecular methods by the use of 16S rDNA amplification, cloning and sequencing.
Twenty-five sputa from CF patients were cultured that yield 33 isolates (13 species) known to be pathogens during CF. For
molecular cloning, 760 clones were sequenced (7.263.9 species/sputum), and 53 different bacterial species were identified
including 16 species of anaerobes (30%). Discrepancies between culture and molecular data were numerous and
demonstrate that accurate identification remains challenging. New or emerging bacteria not or rarely reported in CF
patients were detected including Dolosigranulum pigrum, Dialister pneumosintes, and Inquilinus limosus.
Conclusions/Significance: Our results demonstrate the complex microbial community in sputa from CF patients, especially
anaerobic bacteria that are probably an underestimated cause of CF lung pathology. Metagenomic analysis is urgently
needed to better understand those complex communities in CF pulmonary infections.
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Introduction
Cystic fibrosis (CF) is an autosomal recessive disorder due to
mutations in the Cystic Fibrosis Transmembrane conductance
Regulator (CFTR) gene that is located on chromosome 7 in
human [1]. The bronchopulmonary infections represent the major
problem in CF patients that lead to a decrease of the lung function
and are responsible of a high morbidity and mortality [2].
Although the life expectancy of these patients has increased over
last years, the mortality remains high in patients between 26 and
30 years. It has been demonstrated that accurate antimicrobial
treatment are of great importance to avoid a rapid destruction of
the lung functions and the spread of multidrug-resistant and/or
highly virulent pathogens [3]. Nevertheless, accurate isolation and
identification of bacteria from sputa of CF patients is often
difficult. Indeed, conventional methods used for isolation of
bacteria from sputa usually consist of the use of selective media [4]
adapted to the culture of several pathogens mainly Staphylococcus
aureus, Pseudomonas aeruginosa, Streptococcus pneumoniae, Haemophilus
influenzae, and Burkholderia cepacia. However, these media are not
able to isolate fastidious or emerging bacteria and are often
contaminated with mixed bacteria and/or fungi. Moreover,
mucoid P. aeruginosa usually invades all the agar plates so that it
becomes impossible to isolate other bacteria [5]. It also has been
documented that P. aeruginosa can produce substances that inhibit
the growth of other bacteria [5]. Finally, even if bacteria are
isolated, correct identification is often difficult due to either the
phenotypic variations as frequently reported for P. aeruginosa (lack
of pigments) [6], S. aureus (small colony variants) [7], and B. cepacia
[8] or the fact that some bacteria are not recorded in the databases
of the commercial phenotypic systems currently available.
Molecular biology techniques for correct detection and
identification of bacteria is now widely used in clinical microbi-
ology and also developed for identification of isolates obtained
from CF patients especially for gram-negative nonfermenting
bacilli by the use of 16S rDNA gene sequencing [6,8]. Although
these techniques can identify precisely isolated bacteria, they can
not evaluate bacterial diversity in polymicrobial samples. Other
approaches have been used to identify these bacterial communi-
ties, mainly based on analysis of the sputa by terminal restriction
fragment length polymorphism (RFLP) using the 16S rRNA target
gene [4] or using specific hybridization probes methods [5].
Nevertheless, these techniques present limits, as it can not identify
new or unknown pathogens [4,5].
PLoS ONE | www.plosone.org 1 August 2008 | Volume 3 | Issue 8 | e2908The primary purpose of this study was to compare the
phenotypic identification of bacteria to molecular methods using
16S rDNA amplification, cloning, and sequencing in a series of
sputa from CF patients. The secondary purpose was to evaluate
the bacterial diversity and to describe new or emerging pathogens
colonizing CF lung.
Results
Samples
During a 2 months period (December 2005–January 2006) we
have collected 25 sputa from 16 children (8.9 years65.9) and 9
adults (29 years69.4).
Bacterial culture and identification of the isolates
Among the 16 sputa from children, 20 known pathogens were
isolated from 14 sputa whereas mixed oropharyngeal flora was
retrieved from 2 patients (patient 3 and 7). The conventional
phenotypic identification was as follows: 7 S. aureus,2Stenotropho-
monas maltophilia,1S. pneumoniae,1Escherichia coli,1Achromobacter
xylosoxidans,1Chryseobacterium indologenes,1Moraxella catarrhalis,1
Mycobacterium avium (a positive isolate with Ziehl-Neelsen colora-
tion), and 5 (n=5/20, 25%) isolates without correct identification
(Fig. 1A). Among the 9 sputa from adults, 13 bacteria were isolated
including 5 S. aureus,4P. aeruginosa,1Klebsiella pneumoniae, and 3
(23%) isolates without correct identification (Fig. 1B). Correct
identification for the 8 atypical isolates was achieved after partial
sequencing of 16S rRNA gene leading to S. pneumoniae,2Inquilinus
limosus, A. xylosoxidans, Serratia marcescens, S. aureus, Burkholderia
multivorans, and P. aeruginosa (Table 1).
Analysis of sputa after PCR and cloning
A total of 1,000 clones containing the correct size of the insert
(approximately 1,230 bp) were collected from the 25 sputa. Finally
wehavesequenced 760clones(24clonesfor 15patientsand 40clones
for 10 patients) and 736 exploitable bacterial sequences (96.8%) were
analyzed. All obtained sequences have a sequence similarity score of
$97% when compared with the existing sequences in the GenBank
database except 11 sequences including 4 S. pneumoniae (AE008546,
96%), 3 Streptococcus constellatus (AY277939, 94%), 2 Streptococcus iniae
(AF335573, 95%), 1 H. influenzae (AY613741, 91%) and 1 A.
xylosoxidans (AF531768, 95%). These 11 sequences may be considered
as being obtained from putative new species.
The 736 sequences corresponded to 53 different bacterial species
that are listed in Table 2. The mean number of bacterial species per
sputum was 7.2 bacteria 63.9 [range 1–14] (7.263.5 for the
children and 7.264.7 for the adults). The mean number of detected
species was statistically higher when the number of sequenced clones
was increased (6.064.0 species for 24 sequenced clones versus
9.063.1 species for 40 sequenced clones) (p=0.05) (Figure 2). Of
these 53 species, 9 were previously reported as pathogen in CF
patients and represented 344 clones (46.7%) (Table 2). The other
species were either bacteria from oral flora, especially anaerobic
bacteria, orbacteria detectedinendodontic/peridontic infections, or
bacteria of unknown pathogenicity (392 clones, 53.3%). The
anaerobes represented 30.2% of the detected species (16/53 species)
and 16.2% of the total sequenced clones (119/736 clones) (Table 2).
Comparison between culture and cloning
Among the 33 isolated bacteria from culture, 19 bacteria (57.6%)
were also found after PCR and cloning (blue boxes, Figure 3). Eight
isolates (24.2%) were not found after PCR and cloning (red boxes,
Figure 3) including: 2 S. aureus,1P. aeruginosa,1K. pneumoniae,1M.
avium,1C. indologenes et 2 I. limosus. Interestingly, all these bacteria
were recovered in very small quantity in culture (10
2
2 10
3 CFU/ml)
Figure 1. Bacteria identified by the conventional culture
methods in children (A) and in adults (B).
doi:10.1371/journal.pone.0002908.g001
Table 1. Genotypic identification of the 8 misidentified isolates.
Patient No. Age (year) Phenotypic identification (%) API system 16S rRNA sequencing (GenBank accession number, %)
41 Streptococcus salivarius (99.8%) Streptococcus pneumoniae (AE008546, 96%)
52 Sphingomonas paucimobilis (99.8%)
* Inquilinus limosus (AY043375, 99%)
91 2Achromobacter xylosoxidans (49.5%)
* Achromobacter xylosoxidans (AF411020, 100%)
11 13 Burkholderia cepacia (87.7%)
* Serratia marcescens (AJ550467, 99%)
16 17 Agrobacterium radiobacter (97.7%)
* Inquilinus limosus (AY043375, 99%)
17 18 Orange gram-positive coccus
* Staphylococcus aureus (BX571857, 99%)
19 19 Pseudomonas stutzeri (95%)
* Burkholderia multivorans (Y18703, 99%)
22 30 Multiresistant gram-negative coccobacilli grew on chocolate
Poly ViteX agar but not on MacConKey agar
Pseudomonas aeruginosa (AY631241, 99%)
*isolate grew on Cepacia agar.
doi:10.1371/journal.pone.0002908.t001
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aswell asanaerobes.Six isolatesthat were previouslymisidentified in
culture from patients 4, 9, 11, 17, 19, and 22 could be detected after
PCR and cloning and their identifications were 100% identical to
that of those obtained from direct 16S rRNA sequence of isolates
(Table 1 and yellow boxes, Figure 3).
Conversely, five pathogenic and theoretically cultivable bacte-
rial species were only detected after PCR and cloning in 7 patients
(green boxes, Figure 3) including 1 S. aureus,2P. aeruginosa,2H.
influenzae,1S. pneumoniae, and 1 M. catarrhalis. Interestingly, these 7
patients were known to be chronically infected with these bacteria
and all of them received adapted antimicrobial therapy prior to
the analysis of their sputum sample. Conversely, for the other
patients, they did not receive antibiotics prior to isolation of the
bacteria in their sputa.
Control analysis
In control group consisting of 4 patients with bronchiectasis (1
child and 3 adults), the culture was interpreted as mixed
oropharyngeal flora for 3 patients and H. influenzae was isolated
for one patient. PCR and cloning of these sputa and sequencing of
89 clones showed several pathogens such as S. pneumoniae, H.
influenzae, M. catarrhalis, and Stenotrophomonas maltophilia besides the
oral flora and anaerobes (Figure 3). The mean number of bacterial
species per sputum in bronchiectasis group was 6.8 bacteria 61
[range 6–8] versus 7.2 bacteria 63.9 [range 1–14] in CF group
(p=0.8). Interestingly, the number of different species detected in
CF group (53 species) was statistically higher than in control group
(13 species) (p=0.0004, Relative Risk=1.8).
Discussion
The conventional phenotypic techniques of isolation, identifica-
tion, and evaluation of the antibiotic susceptibility for the pathogens
in sputa from CF patients remain to date the base line in therapeutic
management during the bronchial exacerbations of this disease.
Nevertheless, the applied culture methods have been adapted to
isolate the common bacteria known to be involved in bronchial
infections of CF patients. So they neither allow to evaluate the
Table 2. The bacterial diversity detected using the genomic methods.
Pathogen species No. of clones Other species No. of clones
Achromobacter xylosoxidans
* 9 Abiotrophia defectiva
* 1
Burkholderia multivorans
* 11 Actinomyces sp.
* 2
Haemophilus influenzae
* 7 Bergeyella sp.
{ 1
Moraxella catarrhalis
{ 20 Capnocytophaga sp.
* 1
Pseudomonas aeruginosa
* 99 Carnobacterium sp.
{ 4
Serratia marcescens
{ 3 Dolosigranulum pigrum
{ 8
Staphylococcus aureus
* 129 Eikenella corrodens
*{ 2
Stenotrophomonas maltophilia
* 41 Escherichia coli
* 2
Streptococcus pneumoniae
* 25 Gemella haemolysans
*{ 20
Total (%) 344 (46.7%) Gemella sanguinis
* 2
Granulicatella adiacens
* 5
Anaerobic species No. of clones Granulicatella paradiacens
* 17
Dialister pneumosintes
*{ 1 Kingella denitrificans
*{ 1
Gemella morbillorum
*{ 4 Kingella oralis
*{ 2
Lachnospiraceae genomosp.
*{ 2 Lactobacillus delbruekii
*{ 1
Peptostreptococcus sp.
* 1 Neisseria sp.
* 33
Porphyromonas sp.
* 20 Rothia mucilaginosa
* 4
Prevotella denticola
* 6 Streptococcus anginosus
* 5
Prevotella melaninogenica
* 12 Streptococcus constellatus
*{ 3
Prevotella oris
* 2 Streptococcus cristatus
* 1
Prevotella salivae
* 1 Streptococcus genomosp.
* 24
Prevotella sp.
* 37 Streptococcus gordonii
* 4
Selenomonas infelix
*{ 2 Streptococcus iniae
{ 2
Selenomonas noxia
*{ 1 Streptococcus mitis
* 13
Selenomonas sp.
* 4 Streptococcus parasanguis
* 10
Tannerella forsythensis
*{ 2 Streptococcus salivarius
* 20
Veillonella atypica
* 1 Streptococcus sanguinis
* 2
Veillonella sp.
* 23 Streptococcus sp.
* 83
Total (%) 119 (16.2%) Total (%) 273 (37.1%)
*Species that have been detected either in normal oral flora, endodontic/peridontic infections, VAP, or CF samples using T-RFLP or cloning [4,9,11,13–20].
{First species detection in CF samples using cloning in this study.
doi:10.1371/journal.pone.0002908.t002
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can participate in the physiopathology of the disease.
The bacterial diversity in a complex flora such as sputa from CF
patients was previously studied using RFLP techniques [4,9] or
temporal temperature gradient gel electrophoresis (TTGE)
followed by pyrosequencing [10] that are known to be time-
consuming and are not able to identify new pathogens. Only three
reports have described the amplification of 16S rRNA gene
followed by cloning and sequencing to identify these complex flora
but this was either for a very limited number of patients and a
limited number of clones [4,9] or only from children with CF [11].
This approach has been successfully used for identification of
bacterial species for the diagnosis of other infections such as bone
and joint infections [12], endodontic infections [13–15], peri-
odontitis [16–18], and ventilator-associated pneumonia (VAP)
[19] allowing the detection of fastidious and/or emerging
pathogens. In our study, 57.6% of isolated bacteria were found
only after cloning and sequencing. For the pathogenic species only
detected after amplification and cloning (7 cases), patients had
received an effective antibiotic therapy that can explain the
negativity of the culture. It is important to know that the detection
of bacteria by PCR does not necessarily reflect the viability of these
bacteria. It is also possible that some bacteria can enter viable but
uncultivable state. For the false-negative PCR cloning results, the
load of bacteria on agar was low as compared to oropharyngeal
flora, suggesting that the prevalent flora was amplified preferen-
tially. Another explanation of these discordances could be a low
specificity of the universal primers for some bacteria, especially for
I. limosus and M. avium.
Finally, the analysis of sputa after PCR and cloning enabled us
to obtain, besides the pathogens recovered from culture, 392
additional sequences identifying 44 different bacterial species
including 5 putative new species. These species have been
documented mainly in normal bacterial flora of the oral cavity
[20] and often in endodontic/periodontic infections [13–18] or in
VAP [19] (Table 2). Interestingly, clonal analysis of tongue and
lung samples taken from patients with VAP revealed a wide range
of bacterial diversity in the oral cavity and lung and indicated that
the dorsal surface of the tongue serves as a potential reservoir for
bacterial species involved in VAP [19]. In the case of CF, current
knowledge shows that the pulmonary infections and bronchial
exacerbations must be considered as polymicrobial infections
[4,5,9,10]. Recent works have shown that the bacterial diversity in
sputa of CF patients was much more important than that
previously considered [4,5]. Rogers et al have recently compared
bacterial communities in sputum and mouthwash samples from
patients with CF using T-RFLP and have demonstrated that
sputum from the lungs of these patients is not contaminated by
Figure 2. Box plot graph representing the number of detected
bacterial species in the two groups of patients. Group
1=patients to whom 24 clones from their sputa have been sequenced;
Group 2=patients to whom 40 clones from their sputa have been
sequenced.
doi:10.1371/journal.pone.0002908.g002
Figure 3. Comparison between phenotypic and genotypic detection and identification. The number in the box indicates the number of
clones obtained for each bacterial species in each sputum. C1, C2, C3, and C4 were control analysis. Blue color box=concordant results between PCR-
cloning and culture; red color box=negative PCR-cloning and positive culture; green color box=positive PCR-cloning and negative culture; yellow
color box=misidentified bacteria.
doi:10.1371/journal.pone.0002908.g003
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evidence that the CF lung can be colonised by certain oral
bacterial species [21]. The Table 2 presents the comparison of the
species detected in our study in CF patients with those previously
detected either in normal bacterial flora of the oral cavity [20], in
endodontic/periodontic infections [13–18], in VAP [19], or in CF
samples [4,9,11] using T-RFLP or 16S rDNA clone libraries
analysis. Interestingly, we have found in these patients several
pathogens not isolated in the culture besides the oral flora and
anaerobes like Prevotella and Porphyromonas species.
In our study, we were able to detect 16 anaerobic bacterial
species representing 119 of 736 clones (16.2%). It is not usual to
look for or to isolate anaerobes from sputa of CF patients. A recent
study has described the isolation of a range of anaerobic species in
large numbers and from 64% of sputum samples taken from
patients with CF [22] with the genera Prevotella and Veillonella being
the most frequently isolated [22]. These two genera are also
detected frequently in our work. Because anaerobic bacteria are
naturally resistant to certain antibiotics including aminoglycosides
[23] that are frequently used during CF, one can hypothesize that
these anaerobes may be selected after an elective course of
antibiotics therapy. In the study of Jewes et al., anaerobes were
isolated in about 24% of tested samples during either bronchial
exacerbations or not [24]. The proportion of the detected
anaerobes in two other studies was 16.5% (17/103 clones) [4]
and 26.4% (14/53 clones) [9]. The percentage of anaerobic
bacteria in a recent study in CF patients ranged from 27 to 93% of
the clones examined. Interestingly, such anaerobic bacteria were
rare in CF subjects with typical pathogens [11]. Conversely, in
another work, the colonisation with P. aeruginsa significantly
increased the likelihood that anaerobic bacteria would be present
in the CF sputum [22]. The role of these anaerobes in the
physiopathology of CF remains unclear. However, recent data
demonstrate that the oropharyngeal flora, that are not normally
thought of as serious problems in CF, can induce a positive
regulation (phenomenon of quorum sensing) of genes of virulence
of P. aeruginosa [25]. Conversely, it is also possible that P. aeruginosa
can influence virulence factor genes of secondary pathogens or
those potentially present in the oropharyngeal flora strains [25] that
gain in pathogenicity. Therefore oropharyngeal bacteria likely
participate in disease progression and are probably an underesti-
mated emerging cause of CF lung pathology that should be
considered in the antibiotic strategy. This phenomenon of inter-
cellular communications is also important in the constitution of the
biofilms [26]. Moreover, many studies illustrate that the activity of
several antibiotics including aminoglycosides and quinolones against
P. aeruginosa, residing in a biofilm mode within hypoxic inspissated
airway mucus and undergoing anaerobic metabolism, is significantly
reduced or ineffective under anaerobic conditions than under
aerobic conditions [27–29]. New therapeutic approaches by
inhibition of the phenomenon of quorum sensing and anaerobes
may be useful in the treatment of the respiratory infections in CF
patients as recently demonstrated with azithromycin [30].
Finally, many bacteria identified in our work, like I. limosus, G.
adjacens, R. mucilaginosa, D. pneumosintes, D. pigrum are not classically
described in the expectoration of CF patients. In the study of Harris
et al., potentially novel pathogens in CF subjects were also detected
using rRNAgene librariesincluding the genus Lysobacter,m e m b e r so f
the Coxiellaceae and Rickettsiales, Prevotella denticola,a n dStreptococcus
intermedius [11]. Recently, I. limosus has been documented mainly in
CF patients and was sometimes accompanied with exacerbation or
respiratory decline [31–37]. This bacterium was described in 1999
[34] and was characterized in 2002 [31]. We think that the
prevalence of this multi-resistant bacterium may be underestimated
because of its recent description, its slow growth on selective media,
its absence in the databases of commercial identification kits, and the
need of molecular methods for its identification. D. pigrum was also
recentlyreportedinhumanrespiratorydiseases:acaseofpneumonia
[38],acaseofVAP[39],andfinallyacaseofnosocomialpneumonia
and septicaemia [40]. Human infection diseases caused by D.
pneumosintes (formerly Bacteroides pneumosintes) including supradia-
phragmatic infections in the respiratory tract and brain abscesses
were reviewed in recent study evaluated the antimicrobial
susceptibility of large collection of Dialister clinical isolates [41].
Although the role of these species in the physiopathology of the
pulmonary infections is not known, the description of new bacterial
species represents the first step to understand their possible
implication in the physiopathology of the infection [4,9].
In conclusion, the amplification of 16s DNA followed by cloning
presents considerable advantages to describe and to detect new
bacteria and our result clearly demonstrates that bacterial
population in sputum from CF patients was complex, as the
mean number of detected species increased when we sequenced
more clones, and that accurate identification of these bacteria
remains challenging. It is important to note that the fungi and the
virus participate also effectively in these bronchial polymicrobial
infections that were not studied in our work. Further studies of this
complex flora by metagenomic analysis are currently needed to
better understand these microbial communities, their implication
in treatment and antibiotic resistance, their role in the develop-
ment of chronic respiratory infections, and to identify their clinical
significance in order to find new therapeutic targets.
Materials and Methods
Sample collection
Sputum samples from CF patients (December 2005–January
2006) were collected from two Cystic Fibrosis Treatment Centers
(CFTC): children (patient ,18 years), at Timone children’s
hospital, and adults (patient $18 years), at Ste. Marguerite
hospital in Marseille. Sputa from patients with bronchiectasis were
also collected for control analysis. All sputa were analyzed and
frozen at 220uC for further study. This work has been approved
by the local ethic committee of the IFR48, Faculty of Medicine,
Marseille, France under the reference number 07-008. No written
consent was needed for this work in accordance with the ‘‘LOI nu
2004-800 relative a ` la bioe ´thique’’ published in the ‘‘Journal
Officiel de la Re ´publique Franc ¸aise’’ the 6 August 2004 since no
additional sample was taken for the study.
Bacteriological culture and phenotypic identification
All sputa were inoculated on five agar plates including chocolate
Poly ViteX agar, Columbia colistin-nalidixic acid (CNA) agar,
MacConKey agar, Cepacia agar, and blood agar. All growth
media were purchased from bioMe ´rieux (bioMe ´rieux, Marcy
l’Etoile, France) and were incubated at 37uC for 48 hours except
for Cepacia agar that was purchased from AES laboratory (AES,
Combourg, France) and incubated at 30uC for 5 days. Colonies
growing on the various media were identified using standard
microbiological methods including Gram-staining, catalase and
oxydase activity, susceptibility to optochin, API system (bioMe ´r-
ieux, Marcy l’Etoile, France), VITEK 2 Auto system (bioMe ´rieux,
Marcy l’Etoile, France), and standard procedure for antibiotic
susceptibility testing. When the identification of an isolate was
inaccurate (#95% in commercial identification system) or was not
in accordance with expected antibiotic susceptibility profiles, we
used the amplification and sequencing of 16S rRNA gene to
identify the isolates as previously described [42].
Bacteria in Cystic Fibrosis
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Automatic DNA extraction of sputa was performed in a MagNa
Pure LC instrument (Roche Diagnostics GmbH, Mannheim,
Germany) using the MagNa Pure LC DNA Isolation Kit II (Roche
Diagnostics GmbH, Mannheim, Germany). One hundred micro-
liter of each sample was treated with 200 mL of lysis buffer and
50 mL of proteinase K and was incubated overnight at 56uCa s
recommended by manufacturer. This mixture was shaken in a
tube containing glass beads during 45 seconds then was heated at
100uC for 10 minutes. Then DNA was extracted according to the
manufacturer’s instruction.
Genomic amplification
Amplification of approximately 1,000 base pairs (bp) of the 16S
rRNA gene was carried out with the primer pair 536F [59-
CAGCAGCCGCGGTAATAC] and rp2 [59-ACGGC-
TACCTTGTTACGACTT] (Eurogentec, Seraing, Belgium)
[12]. The PCR reaction mixture (final volume, 50 mL) contained
5 mL of dNTP (2 mM of each nucleotide), 5 mLo f1 0 6 DNA
polymerase buffer (QIAGEN, Courtaboeuf, France), 2 mLo f
MgCl2 (25 mM), 0.25 mL of HotStarTaq DNA polymerase
(1.25 U)(QIAGEN, Courtaboeuf, France), 1 mL of each primer
536F, rp2 (10 pmol/mL), and 5 mL of extracted DNA. PCR was
performed with a preliminary step at 95uC for 15 minutes
followed by 35 cycles of 94uC for 1 minute, 62uC for 30 seconds,
and 72uC for 1 minute and final step of extension at 72uC for
5 minutes. Then PCR products were purified using the Nucleo-
FastH 96 PCR Kit (MACHEREY-NAGEL, Hoerdt, France)
according to the manufacturer’s instructions.
Cloning procedures
Cloning of purified PCR products was performed using the
pGEMH -T Easy Vector System 2 Kit (Promega, Madison, USA)
as described by the manufacturer. Finally 20 ml of the bacterial
suspension were resuspended in a tube containing 80 mLo fL B
Agar (USB, Cleveland, Ohio, USA). This suspension was plated
onto LB Agar plates supplemented with Ampicilline (100 mg/mL),
X-GAL (80 mg/mL), and IPTG (120 mg/mL) and the plates were
incubated overnight at 37uC. Blue/white colonies were screened
using these plates. Forty white colonies were collected from each
plate and stored in water at 220uC.
Insert amplification
The colonies were analysed by PCR. The reaction mixture
contained 2 mL of bacterial suspension, 5 mL of dNTP (2 mM of
each nucleotide), 5 mL of PCR reaction buffer (100 mM Tris-HCl,
15 mM MgCl2, 500 mM KCl, pH 8,3) (Roche Diagnostics
GmbH, Mannheim, Germany), 0.25 mL (1.25 U) of Taq DNA
polymerase (Roche Diagnostics GmbH, Mannheim, Germany)
and 1 mL of each primer (10 pmol/mL) M13d [59-GTAAAAC-
GACGGCCAG], M13r [59-CAGGAAACAGCTATGAC](Euro-
genetec, Seraing, Belgium) in a final volume of 50 mL. The PCR
mixture was preheated at 90uC for 10 minutes, followed by
amplification under the following conditions: denaturation at 94uC
for 50 seconds, annealing at 57uC for 1 minute, and elongation at
72uC for 2 minutes. A total of 35 cycles were performed and
followed by a final elongation step at 72uC for 10 minutes. Correct
sizes of the inserts were purified using the NucleoFastH 96 PCR
Kit (MACHEREY-NAGEL, Hoerdt, France).
Sequencing and informative data analysis
Purified PCR-amplified 16S rRNA inserts were sequenced in
both directions using the Big DyeH Terminator V1,1 Cycle
Sequencing Kit (Applied Biosystems, Courtaboeuf, France). The
primers used for sequencing were M13d and M13r. The
sequencing products were then run on an ABI PRISM 3130
automated sequencer (Applied Biosystems, Foster city, CA, USA).
Finally the identification of bacteria was determined by comparing
the obtained sequence with that of existing sequences in the
GenBank database using the BLAST program available at the
National Center for Biotechnology Information Web site (http://
www.ncbi.nlm.nih.gov/, BLAST).
Phylogenetic and statistical analysis
Data including the mean number of detected species per
sputum (for 24 and 40 clones – in CF and control samples) and the
number of different species detected in CF and bronchiectasis
group were compared by chi-square test using Epi Info, version
3.4.1 (Centers for Disease Control and Prevention, Atlanta, Ga.,
USA). p values of #0.05 were considered statistically significant.
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